- Home
- XP vs QGEN Comparison
XP vs QGEN Comparison
Compare XP & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XP
- QGEN
- Stock Information
- Founded
- XP 2001
- QGEN 1986
- Country
- XP Cayman Islands
- QGEN Netherlands
- Employees
- XP N/A
- QGEN N/A
- Industry
- XP Investment Bankers/Brokers/Service
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XP Finance
- QGEN Health Care
- Exchange
- XP Nasdaq
- QGEN Nasdaq
- Market Cap
- XP 9.1B
- QGEN 10.3B
- IPO Year
- XP 2019
- QGEN 1996
- Fundamental
- Price
- XP $17.34
- QGEN $46.80
- Analyst Decision
- XP Strong Buy
- QGEN Buy
- Analyst Count
- XP 6
- QGEN 8
- Target Price
- XP $23.67
- QGEN $51.01
- AVG Volume (30 Days)
- XP 7.2M
- QGEN 1.1M
- Earning Date
- XP 11-18-2025
- QGEN 11-05-2025
- Dividend Yield
- XP 7.96%
- QGEN 3.23%
- EPS Growth
- XP 18.07
- QGEN 405.09
- EPS
- XP 1.67
- QGEN 1.69
- Revenue
- XP $3,085,301,717.00
- QGEN $2,040,067,000.00
- Revenue This Year
- XP $18.43
- QGEN $7.37
- Revenue Next Year
- XP $13.18
- QGEN $5.70
- P/E Ratio
- XP $10.37
- QGEN $27.64
- Revenue Growth
- XP 6.65
- QGEN 5.15
- 52 Week Low
- XP $10.82
- QGEN $37.63
- 52 Week High
- XP $20.64
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- XP 37.01
- QGEN 55.40
- Support Level
- XP $18.47
- QGEN $43.74
- Resistance Level
- XP $19.21
- QGEN $46.23
- Average True Range (ATR)
- XP 0.63
- QGEN 0.67
- MACD
- XP -0.27
- QGEN 0.26
- Stochastic Oscillator
- XP 5.49
- QGEN 97.14
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).